Portal de Periódicos da CAPES

Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

2023; Elsevier BV; Volume: 370; Linguagem: Inglês

10.1016/j.atherosclerosis.2023.02.007

1879-1484

Alberico L. Catapano, Lâle Tokgözoğlu, Maciej Banach, Marta Gazzotti, Elena Olmastroni, Manuela Casula, Kausik K. Ray, Alaa Abdelrazik, Alberto Mello e Silva, A. Vonbank, Alexandros D. Tselepis, Alper Sönmez, Angelina Passaro, Anja Vogt, Ann C. Mertens, Ann Verhaegen, Arman Postadzhiyan, Bahadır Kırılmaz, Barış Güngör, Berit Storgaard Hedegaard, Bertrand Cariou, Britta Otte, Buğra Özkan, Christ Berge, Christoph Ebenbichler, Christoph J. Binder, Christoph B. Olivier, Conrad Azzopardi, Cristina Soler, Dan Gaiţă, Daniel Weghuber, Dilek Ural, Diogo Cruz, Dragoş Vinereanu, E Pencu, Emil Hagström, Erik Berg Schmidt, Erik S.G. Stroes, Evangelos Liberopoulos, Fabian Demeure, Fabio Fimiani, Fabio Pellegatta, Fahrı Bayram, Finn Lund Henriksen, Florian Höllerl, Francesco Cipollone, Francisco Araújo, Franck Boccara, François Paillard, Gábor Simonyi, Gabriella Iannuzzo, Giuseppe Mandraffino, Graham Bayly, Gustavs Latkovskis, György Paragh, Hana Rosolová, Handrean Soran, Helle Kanstrup, Hermann Toplak, Hülya Çiçekcioğlu, İnanç Artaç, Ioanna Gouni‐Berthold, Irfan Duzen, Isabel Palma, István Reiber, Iveta Dzīvīte-Krišāne, Jeanine E. Roeters van Lennep, J Balligand Jean-Luc, Joao C. Porto, João Sequeira Duarte, Johan De Sutter, José López‐Miranda, José María Mostaza, Jurgita Plisienė, Kadir Uğur Mert, Kirsten B. Holven, Kjetil Retterstøl, Kristian Korsgaard Thomsen, Lâle Tokgözoğlu, László Bajnok, Lia E. Bang, Liliana Grigore, L. Masana, Lοukianos S. Rallidis, Maciej Banach, Małgorzata Waluś‐Miarka, Manuel Castro Cabezas, Marcello Arca, Margus Viigimaa, Martin P. Bogsrud, Matej Mlinarič, Matteo Pirro, Maurizio Averna, Meral Kayıkçıoğlu, Merete Heitmann, Mette Rauhe Mouridsen, Michal Vrablı́k, Michel Farnier, Michel R. Langlois, Milad Khedr, Muge Ildizli Demirbas, Myra Tilney, Nadia Citroni, Niels P. Riksen, Nikolay Runev, Nora Kupstytė-Krištaponė, Olena Mitchenko, Oliver Weingärtner, Öner Özdoğan, Ovidio Muñiz-Grijalvo, Özcan Başaran, Pankaj Gupta, Paolo Parini, Patrizia Suppressa, Paul Downie, Pavel Ješina, Pavel Kraml, Paweł Burchardt, Pedro Valdivielso, Pedro von Hafe, Peter Fasching, Philippe Moulin, Quitéria Rato, Reinhold Innerhofer, Renata Cífková, René Valéro, Roberto Scicali, Robin Urbánek, Roma Kavaliauskiene, Roman Cibulka, Sabina Zambon, Sergio D’Addato, Stanislav Zemek, S. Romeo, Stephanie Könemann, Susanne Greber‐Platzer, Thomas M. Stulnig, Thomas Muhr, Tina Khan, Tomáš Freiberger, Tomáš Šálek, Tomas Vasylius, Ulrich Laufs, Ulrike Schatz, Urh Grošelj, Victoria Marco-Benedí, Vincent Maher, V. Bláha, Vladimír Soška, Volker Schettler, Wolfgang Reinhardt, Xavier Pintó, Yoto Yotov, Žaneta Petrulionienė, Željko Reiner,

Coronary Interventions and Diagnostics

Background and aimsThe European Atherosclerosis Society (EAS) Lipid Clinics Network promoted a survey in order to identify and understand how and when lipoprotein(a) [Lp(a)] is tested and clinically evaluated in lipid clinics throughout Europe, and the challenges that may prevent evaluation from being carried out.MethodsThis survey was divided into three areas of inquiry: background and clinical setting information of clinicians, questions for doctors who claimed not to measure Lp(a), in order to understand what were the reasons for not ordering the test, and questions for doctors who measure Lp(a), to investigate the use of this value in the management of patients.ResultsA total of 151 centres clinicians filled in the survey, out of 226 invited. The proportion of clinicians who declare to routinely measure Lp(a) in clinical practice was 75.5%. The most common reasons for not ordering the Lp(a) test were the lack of reimbursement or of treatment options, the non-availability of Lp(a) test, and the high cost of performing the laboratory test. The availability of therapies targeting this lipoprotein would result in a greater propensity of clinicians to start testing Lp(a). Among those who declared to routinely measure Lp(a), the Lp(a) measurement is mostly requested to further stratify patients' cardiovascular risk, and half of them recognized 50 mg/dL (approx. 110 nmol/L) as the threshold for increased cardiovascular risk due.ConclusionsThese results warrant for a great deal of effort from scientific societies to address the barriers that limit the routine use of the measurement of Lp(a) concentration and to recognise the importance of Lp(a) as a risk factor.